COMbination of Bipolar Androgen Therapy and Nivolumab

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

October 27, 2022

Study Completion Date

January 6, 2023

Conditions
Castration-resistant Prostate CancerMetastatic Prostate CancerProstate Cancer
Interventions
DRUG

Testosterone cypionate

Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.

DRUG

Nivolumab

Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.

Trial Locations (3)

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab | Biotech Hunter | Biotech Hunter